Alendronate + Placebo
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis, Osteoporosis, Bone Diseases, Metabolic
Trial Timeline
Dec 1, 2003 → Aug 1, 2006
NCT ID
NCT00157690About Alendronate + Placebo
Alendronate + Placebo is a approved stage product being developed by Merck for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00157690. Target conditions include Cystic Fibrosis, Osteoporosis, Bone Diseases, Metabolic.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00157690 | Approved | Completed |
Competing Products
20 competing products in Cystic Fibrosis